Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 2/20 | 0.34 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18364935 | 1.00 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL15151056 | 1.00 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL8498418 | 1.00 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL9527531 | 1.00 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL7057539 | 1.00 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL6906651 | 1.00 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL8854257 | 1.00 | KMT2A (0.54) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL10005703 | 0.98 | KMT2A (0.52) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL14233382 | 0.98 | KMT2A (0.51) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 | |
| SCHEMBL820099 | 0.98 | KMT2A (0.51) | KMT2AMEN1KDM4CALDH1A1L3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107567442-B | Inhibitors of hepatitis C virus polymerase | 共晶制药公司 | 2021-05-25 | — | — | CN | disclosed |
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| US-20200255393-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2020-08-13 | — | — | US | disclosed |
| US-20200255393-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2020-08-13 | — | — | US | disclosed |
| US-10464914-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| US-10464914-B2 | Inhibitors of hepatitis C virus polymerase | COCRYSTAL PHARMA, INC. (US) | 2019-11-05 | — | — | US | disclosed |
| EP-3274340-B1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA INC (US) | 2019-07-17 | — | — | EP | disclosed |
| EP-3274340-B1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA INC (US) | 2019-07-17 | — | — | EP | disclosed |
| US-20180050998-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | COCRYSTAL PHARMA, INC. | 2018-02-22 | — | — | US | disclosed |
| US-20100014010-A1 | FORMULATIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2010-01-21 | — | — | US | disclosed |
| US-20090326186-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPTICAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| US-20090323012-A1 | LIQUID CRYSTAL COMPOSITIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | TRANSITIONS OPITCAL, INC. (US) | 2009-12-31 | — | — | US | disclosed |
| EP-1751126-A1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | Solvay Pharmaceuticals GmbH (DE) | 2007-02-14 | — | — | EP | disclosed |
| US-7074822-B2 | Alkyl carbamate-substituted β-lactones, process for their preparation, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2006-07-11 | — | — | US | disclosed |
| US-20050197386-A1 | Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-08 | — | — | US | disclosed |
| WO-2005080366-A1 | ALKYL CARBAMATE-SUBSTITUTED BUTYROLACTONES SERVING AS LIPASE INHIBITORS | SOLVAY PHARMACEUTICALS GMBH (DE) | 2005-09-01 | — | — | WO | disclosed |
| US-5447942-A | Treatment of bronchoconstriction | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1995-09-05 | — | — | US | disclosed |
| US-4990505-A | Treating asthma, bronchitis; adrenergic stimulants | GLAXO GROUP LIMITED (GB) | 1991-02-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100014010-A1 | FORMULATIONS COMPRISING MESOGEN CONTAINING COMPOUNDS | MYOC, RARG, MTX2 | KMT2A 4121/4885MEN1 84/4885KDM4C 3058/4885 |
| US-20200255393-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLI, POLR2E, POLR2H | KMT2A 3562/4885MEN1 4697/4885KDM4C 2864/4885 |
| US-10464914-B2 | Inhibitors of hepatitis C virus polymerase | POLI, POLR2E, POLR2H | KMT2A 3562/4885MEN1 4697/4885KDM4C 2864/4885 |
| US-20090326186-A1 | MESOGEN CONTAINING COMPOUNDS | MYOC, BMP2, RARG | KMT2A 3837/4885MEN1 117/4885KDM4C 3160/4885 |
| US-20090323011-A1 | MESOGEN CONTAINING COMPOUNDS | MYOC, BMP2, RARG | KMT2A 3837/4885MEN1 117/4885KDM4C 3160/4885 |
| US-20050197386-A1 | Alkyl carbamate-substituted beta-lactones, process and intermediate products for their preparation, and pharmaceutical compositions containing them | PNLIP, CEL, LIPE | KMT2A 3632/4885MEN1 1744/4885KDM4C 1378/4885 |
| US-10947210-B2 | Inhibitors of Hepatitis C virus polymerase | POLI, POLR2E, POLR2H | KMT2A 3562/4885MEN1 4697/4885KDM4C 2864/4885 |
| US-20180050998-A1 | INHIBITORS OF HEPATITIS C VIRUS POLYMERASE | POLI, POLR2E, POLR2H | KMT2A 3562/4885MEN1 4697/4885KDM4C 2864/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.